Tenax Therapeutics Q3 net loss $4.0M; raised $100M private placement

TENAX THERAPEUTICS, INC.

2025-Q3 EPS reported -$1.37 vs consensus -$0.32 ▼ miss (-329.7%)

Net loss of $4.0M for Q3 2024 vs $2.0M in Q3 2023; R&D expenses $3.1M (up from $1.1M).
Cash, cash equivalents and investments $98.3M as of Sept 30, 2024, vs $9.8M at Dec 31, 2023.
Closed private placement in Aug 2024 yielding approximately $100M gross proceeds.
Phase 3 LEVEL study for levosimendan ongoing: 52 investigative sites initiated, enrolling patients.
Cash runway projected through end of 2027 based on current operating plan.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.